Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%

• Main Authors: Bergmann MT, Williams JI, Gomes PJ
• Format: Article
• Language: English
• Published: Dove Medical Press 2014-08-01
• Series: Clinical Ophthalmology
• Online Access: http://www.dovepress.com/treatment-of-allergic-conjunctivitis-with-bepotastine-besilate-ophthal-peer-reviewed-article-OPTH

Mark T Bergmann,1 Jon I Williams,2 Paul J Gomes3On behalf of the Bepotastine Besilate Ophthalmic Solutions Clinical Study Group 1Eye Care Associates of Greater Cincinnati, Inc., Cincinnati, OH, USA; 2Bausch + Lomb, Irvine, CA, USA; 3Ora, Inc., Andover, MA, USA Purpose: To examine the pooled per-protocol ocular end points from two conjunctival allergen challenge (CAC) clinical trials of the dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%.Methods: Two Phase III, placebo-controlled, double-masked, randomized clinical trials were conducted at a total of six separate centers using the CAC model of allergic conjunctivitis. The same study design was employed for both clinical trials, with subjects randomly assigned to either BBOS 1.5% (n=78) or placebo (n=79) treatment. Each subject received one eye drop of the test agent bilaterally at different study visits 15 minutes, 8 hours, or 16 hours prior to a CAC. Primary ocular end points included changes in ocular itching reported at 3, 5, and 7 minutes and conjunctival hyperemia assessed at 7, 15, and 20 minutes following each CAC. Secondary ocular end points included chemosis as well as episcleral and ciliary hyperemia judged by investigators, and tearing (scored as either absent or present) and eyelid swelling judged by subjects.Results: A statistically significant reduction in ocular itching was observed for BBOS 1.5% treatment compared to placebo at all time points (P<0.0001), while measures for onset and 8-hour persistence of action also reached clinical significance (ie, ≥1.0 unit difference) at a majority of time points. In addition, a significant reduction in conjunctival hyperemia was achieved at a majority of time points during the onset of action CAC test. Secondary end points were also significantly improved compared to placebo, most prominently for reduced tearing at all study visits and reduced eyelid swelling at the onset of action and 8-hour study visits. Adverse events were generally mild and transient.Conclusion: BBOS 1.5% rapidly reduced CAC-induced ocular itching with duration of effectiveness of at least 8 hours after dosing. Certain secondary signs of inflammation were also significantly reduced. Keywords: allergen challenge, antihistamine, itching, Bepreve